| #1 | SASP-Mediated Complement Cascade Amplification | C1Q/C3 | 0.703 | $0.78 | sda-2026-04-01-gap-0 |
| #2 | TREM2-Dependent Microglial Senescence Transition | TREM2 | 0.692 | $0.80 | SDA-2026-04-03-gap-a |
| #3 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.681 | $0.80 | SDA-2026-04-03-26abc |
| #4 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.677 | $0.51 | SDA-2026-04-03-26abc |
| #5 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.670 | $0.77 | SDA-2026-04-04-gap-e |
| #6 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.665 | $0.72 | sda-2026-04-01-gap-0 |
| #7 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia | ACSL4 | 0.662 | $0.67 | SDA-2026-04-03-gap-s |
| #8 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.648 | $0.76 | SDA-2026-04-01-gap-l |
| #9 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.631 | $0.75 | SDA-2026-04-01-gap-l |
| #10 | Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation | HCRTR1/HCRTR2 | 0.623 | $0.72 | sda-2026-04-01-gap-v |
| #11 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | TLR4 | 0.617 | $0.59 | SDA-2026-04-01-gap-2 |
| #12 | APOE-Dependent Autophagy Restoration | MTOR | 0.615 | $0.66 | sda-2026-04-01-gap-a |
| #13 | DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxicity Without Directly Targeting Tau | MAP2K7/MAP3K12 | 0.609 | $0.62 | SDA-2026-04-15-gap-p |
| #14 | Digital Twin-Guided Metabolic Reprogramming | PPARGC1A/PRKAA1 | 0.605 | $0.57 | sda-2026-04-01-gap-0 |
| #15 | Senescence-Activated NAD+ Depletion Rescue | CD38/NAMPT | 0.604 | $0.56 | sda-2026-04-01-gap-0 |
| #16 | Multi-Modal Stress Response Harmonization | NR3C1/CRH/TNFA | 0.601 | $0.48 | sda-2026-04-01-gap-0 |
| #17 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #18 | SASP-Driven Aquaporin-4 Dysregulation | AQP4 | 0.590 | $0.54 | sda-2026-04-01-gap-0 |
| #19 | H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance | TREM2 | 0.588 | $0.59 | SDA-2026-04-14-gap-p |
| #20 | Prefrontal sensory gating circuit restoration via PV interneuron enhancement | PVALB | 0.587 | $0.52 | SDA-2026-04-03-26abc |
| #21 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.584 | $0.53 | sda-2026-04-01-gap-0 |
| #22 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.584 | $0.48 | SDA-2026-04-01-gap-2 |
| #23 | TREM2 Agonism to Reprogram Infiltrated Monocytes Toward Neuroprotective Phenotype | TREM2 | 0.584 | $0.57 | SDA-2026-04-13-gap-d |
| #24 | DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization | DAPK1 | 0.579 | $0.58 | SDA-2026-04-15-gap-p |
| #25 | HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stability | HDAC6 | 0.577 | $0.58 | SDA-2026-04-13-gap-d |
| #26 | PARP1 Inhibition Therapy | PARP1 | 0.575 | $0.52 | sda-2026-04-01-gap-0 |
| #27 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.570 | $0.66 | sda-2026-04-01-gap-v |
| #28 | TREM2 Signaling Bifurcation with Independent TYROBP-Independent Homeostatic Maintenance | TREM2 | 0.567 | $0.57 | SDA-2026-04-14-gap-p |
| #29 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.566 | $0.56 | sda-2026-04-01-gap-0 |
| #30 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.565 | $0.55 | sda-2026-04-01-gap-0 |
| #31 | SASP-Mediated Cholinergic Synapse Disruption | MMP2/MMP9 | 0.564 | $0.51 | sda-2026-04-01-gap-0 |
| #32 | Selective HDAC3 Inhibition with Cognitive Enhancement | HDAC3 | 0.563 | $0.54 | SDA-2026-04-04-gap-e |
| #33 | Competitive APOE4 Domain Stabilization Peptides | APOE | 0.561 | $0.51 | sda-2026-04-01-gap-0 |
| #34 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.559 | $0.54 | SDA-2026-04-04-gap-e |
| #35 | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | GPR109A | 0.559 | $0.53 | SDA-2026-04-01-gap-2 |
| #36 | Adenosine-Astrocyte Metabolic Reset | ADORA2A | 0.557 | $0.51 | sda-2026-04-01-gap-v |
| #37 | Purinergic Signaling Polarization Control | P2RY1 and P2RX7 | 0.554 | $0.53 | sda-2026-04-01-gap-0 |
| #38 | Senescent Microglia Resolution via Maresins-Senolytics Combination | BCL2L1 | 0.552 | $0.64 | sda-2026-04-01-gap-0 |
| #39 | Blood-Brain Barrier SPM Shuttle System | TFRC | 0.550 | $0.59 | sda-2026-04-01-gap-0 |
| #40 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.547 | $0.56 | sda-2026-04-01-gap-v |
| #41 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.546 | $0.56 | sda-2026-04-01-gap-v |
| #42 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.545 | $0.53 | sda-2026-04-01-gap-0 |
| #43 | Retinal Vascular Microcirculation Rescue | PDGFRB/ANGPT1 | 0.542 | $0.55 | sda-2026-04-01-gap-0 |
| #44 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.542 | $0.55 | sda-2026-04-01-gap-0 |
| #45 | ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling | ABCA7 + TREM2 (combinatorial) | 0.538 | $0.54 | SDA-2026-04-14-gap-p |
| #46 | Glymphatic System-Enhanced Antibody Clearance Reversal | AQP4 | 0.537 | $0.51 | sda-2026-04-01-gap-0 |
| #47 | Senescence-Induced Lipid Peroxidation Spreading | GPX4/SLC7A11 | 0.533 | $0.54 | sda-2026-04-01-gap-0 |
| #48 | Circadian-Synchronized LRP1 Pathway Activation | LRP1, MTNR1A, MTNR1B | 0.526 | $0.53 | sda-2026-04-01-gap-0 |
| #49 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.526 | $0.53 | sda-2026-04-01-gap-0 |
| #50 | Vagal Afferent Microbial Signal Modulation | GLP1R, BDNF | 0.521 | $0.50 | SDA-2026-04-01-gap-2 |
| #51 | Phase-Separated Organelle Targeting | G3BP1 | 0.521 | $0.53 | sda-2026-04-01-gap-0 |
| #52 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.519 | $0.49 | analysis-SEAAD-20260 |
| #53 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.518 | $0.48 | analysis-SEAAD-20260 |
| #54 | Membrane Cholesterol Gradient Modulators | ABCA1/LDLR/SREBF2 | 0.517 | $0.46 | SDA-2026-04-01-gap-l |
| #55 | Temporal Decoupling via Circadian Clock Reset | CLOCK | 0.516 | $0.36 | sda-2026-04-01-gap-0 |
| #56 | Epigenetic Memory Erasure via TET2 Activation | TET2 | 0.515 | $0.48 | sda-2026-04-01-gap-0 |
| #57 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | LOX/LOXL1-4 | 0.515 | $0.52 | sda-2026-04-01-gap-v |
| #58 | Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement | COX4I1 | 0.514 | $0.49 | sda-2026-04-01-gap-v |
| #59 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication | CHRNA7 | 0.512 | $0.52 | SDA-2026-04-01-gap-2 |
| #60 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.511 | $0.52 | sda-2026-04-01-gap-0 |
| #61 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.511 | $0.48 | sda-2026-04-01-gap-0 |
| #62 | Noradrenergic-Tau Propagation Blockade | ADRA2A | 0.510 | $0.52 | sda-2026-04-01-gap-v |
| #63 | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | APOE, LRP1, LDLR | 0.509 | $0.52 | sda-2026-04-01-gap-0 |
| #64 | Context-Dependent CRISPR Activation in Specific Neuronal Subtypes | Cell-type-specific essential genes | 0.509 | $0.48 | SDA-2026-04-03-gap-c |
| #65 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.509 | $0.36 | SDA-2026-04-03-gap-s |
| #66 | Aquaporin-4 Polarization Rescue | AQP4 | 0.507 | $0.52 | sda-2026-04-01-gap-0 |
| #67 | Mechanosensitive Ion Channel Reprogramming | PIEZO1 and KCNK2 | 0.505 | $0.51 | sda-2026-04-01-gap-0 |
| #68 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | SDC1 | 0.505 | $0.51 | sda-2026-04-01-gap-v |
| #69 | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | CX3CR1 | 0.503 | $0.51 | sda-2026-04-01-gap-v |
| #70 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.498 | $0.51 | sda-2026-04-01-gap-0 |
| #71 | GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease | GAS6/TAM receptor complex | 0.498 | $0.51 | SDA-2026-04-14-gap-p |
| #72 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | GJA1 | 0.497 | $0.51 | sda-2026-04-01-gap-v |
| #73 | Proteostasis Enhancement via APOE Chaperone Targeting | HSPA1A | 0.496 | $0.49 | sda-2026-04-01-gap-a |
| #74 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.496 | $0.51 | SDA-2026-04-01-gap-l |
| #75 | Autophagosome Maturation Checkpoint Control | STX17 | 0.494 | $0.50 | sda-2026-04-01-gap-0 |
| #76 | Sleep Spindle-Synaptic Plasticity Enhancement | CACNA1G | 0.491 | $0.50 | sda-2026-04-01-gap-v |
| #77 | Stress Granule Phase Separation Modulators | G3BP1 | 0.490 | $0.50 | sda-2026-04-01-gap-v |
| #78 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.489 | $0.50 | sda-2026-04-01-gap-0 |
| #79 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.489 | $0.50 | sda-2026-04-01-gap-0 |
| #80 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.488 | $0.49 | sda-2026-04-01-gap-9 |
| #81 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.488 | $0.50 | sda-2026-04-01-gap-v |
| #82 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | CSGA | 0.488 | $0.50 | SDA-2026-04-01-gap-2 |
| #83 | Gut Barrier Permeability-α-Synuclein Axis Modulation | CLDN1, OCLN, ZO1, MLCK | 0.487 | $0.50 | SDA-2026-04-01-gap-2 |
| #84 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.487 | $0.47 | SDA-2026-04-04-gap-t |
| #85 | APOE4-Selective Lipid Nanoemulsion Therapy | APOE | 0.486 | $0.49 | sda-2026-04-01-gap-a |
| #86 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | HMGCR, LDLR, APOE regulatory regions | 0.484 | $0.44 | SDA-2026-04-03-gap-c |
| #87 | Perforant Path Presynaptic Terminal Protection Strategy | PPARGC1A | 0.484 | $0.49 | sda-2026-04-01-gap-0 |
| #88 | Microglial Purinergic Reprogramming | P2RY12 | 0.483 | $0.49 | sda-2026-04-01-gap-0 |
| #89 | Microglial Efferocytosis Enhancement via GPR32 Superagonists | CMKLR1 | 0.483 | $0.49 | sda-2026-04-01-gap-0 |
| #90 | Chaperone-Mediated APOE4 Refolding Enhancement | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | 0.482 | $0.49 | sda-2026-04-01-gap-0 |
| #91 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.481 | $0.49 | sda-2026-04-01-gap-0 |
| #92 | Circadian Rhythm Entrainment of Reactive Astrocytes | BMAL1 | 0.481 | $0.49 | sda-2026-04-01-gap-0 |
| #93 | Tau-Independent Microtubule Stabilization via MAP6 Enhancement | MAP6 | 0.480 | $0.49 | sda-2026-04-01-gap-0 |
| #94 | Purinergic P2Y12 Inverse Agonist Therapy | P2RY12 | 0.480 | $0.49 | sda-2026-04-01-gap-v |
| #95 | Complement C1q Mimetic Decoy Therapy | C1QA | 0.479 | $0.49 | sda-2026-04-01-gap-v |
| #96 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.479 | $0.49 | sda-2026-04-01-gap-0 |
| #97 | APOE-TREM2 Interaction Modulation | TREM2 | 0.479 | $0.49 | sda-2026-04-01-gap-a |
| #98 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.479 | $0.49 | SDA-2026-04-04-gap-e |
| #99 | APOE Isoform Expression Across Glial Subtypes | APOE | 0.476 | $0.47 | analysis-SEAAD-20260 |
| #100 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.476 | $0.48 | sda-2026-04-01-gap-0 |
| #101 | Ocular Immune Privilege Extension | FOXP3/TGFB1 | 0.474 | $0.48 | sda-2026-04-01-gap-0 |
| #102 | TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking | TFAM | 0.474 | $0.48 | sda-2026-04-01-gap-v |
| #103 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.471 | $0.48 | sda-2026-04-01-gap-0 |
| #104 | Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons | C4B | 0.470 | $0.48 | SDA-2026-04-03-gap-a |
| #105 | Magnetosonic-Triggered Transferrin Receptor Clustering | TFR1 | 0.470 | $0.48 | sda-2026-04-01-gap-0 |
| #106 | TET2-Mediated Demethylation Rejuvenation Therapy | TET2 | 0.469 | $0.48 | sda-2026-04-01-gap-v |
| #107 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.468 | $0.48 | SDA-2026-04-01-gap-l |
| #108 | Epigenetic Memory Reprogramming for Alzheimer's Disease | BDNF, CREB1, synaptic plasticity genes | 0.467 | $0.48 | SDA-2026-04-03-gap-c |
| #109 | Glycosaminoglycan Template Disruption Approach | HSPG2 | 0.464 | $0.47 | sda-2026-04-01-gap-9 |
| #110 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.463 | $0.47 | sda-2026-04-01-gap-0 |
| #111 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.463 | $0.47 | sda-2026-04-01-gap-0 |
| #112 | Cryptic Exon Silencing Restoration | TARDBP | 0.462 | $0.47 | sda-2026-04-01-gap-v |
| #113 | HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance | HDAC6 | 0.459 | $0.47 | SDA-2026-04-13-gap-d |
| #114 | TREM2 Activation as an Amplification Node for R136S Protection | TREM2 | 0.459 | $0.46 | SDA-2026-04-13-gap-p |
| #115 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | APOE | 0.459 | $0.47 | sda-2026-04-01-gap-0 |
| #116 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.459 | $0.47 | sda-2026-04-01-gap-v |
| #117 | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | SLC16A1 | 0.455 | $0.42 | SDA-2026-04-03-gap-s |
| #118 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.455 | $0.46 | sda-2026-04-01-gap-0 |
| #119 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering | TDC | 0.452 | $0.46 | SDA-2026-04-01-gap-2 |
| #120 | Hypocretin-Neurogenesis Coupling Therapy | HCRT | 0.452 | $0.46 | sda-2026-04-01-gap-v |
| #121 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.451 | $0.46 | SDA-2026-04-03-gap-c |
| #122 | Cross-Seeding Prevention Strategy | TARDBP | 0.451 | $0.46 | sda-2026-04-01-gap-v |
| #123 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation | GJA1 | 0.450 | $0.46 | sda-2026-04-01-gap-2 |
| #124 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.449 | $0.46 | sda-2026-04-01-gap-0 |
| #125 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | SIRT3 | 0.448 | $0.46 | SDA-2026-04-04-gap-e |
| #126 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.448 | $0.46 | SDA-2026-04-01-gap-2 |
| #127 | Reelin-Mediated Cytoskeletal Stabilization Protocol | RELN | 0.448 | $0.46 | sda-2026-04-01-gap-0 |
| #128 | Axonal RNA Transport Reconstitution | HNRNPA2B1 | 0.446 | $0.46 | sda-2026-04-01-gap-v |
| #129 | Excitatory Neuron Vulnerability via SLC17A7 Downregulation | SLC17A7 | 0.445 | $0.45 | analysis-SEAAD-20260 |
| #130 | HCN1-Mediated Resonance Frequency Stabilization Therapy | HCN1 | 0.444 | $0.45 | sda-2026-04-01-gap-0 |
| #131 | Mitochondrial Transfer Pathway Enhancement | MIRO1 | 0.443 | $0.45 | sda-2026-04-01-gap-0 |
| #132 | Pericyte Contractility Reset via Selective PDGFR-β Agonism | PDGFRB | 0.443 | $0.45 | sda-2026-04-01-gap-v |
| #133 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.443 | $0.45 | sda-2026-04-01-gap-0 |
| #134 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.442 | $0.43 | SDA-2026-04-04-gap-t |
| #135 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.440 | $0.45 | SDA-2026-04-01-gap-2 |
| #136 | APOE Isoform Conversion Therapy | APOE | 0.437 | $0.45 | sda-2026-04-01-gap-a |
| #137 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.437 | $0.45 | SDA-2026-04-04-gap-t |
| #138 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.437 | $0.45 | sda-2026-04-01-gap-v |
| #139 | Complement C1q Subtype Switching | C1QA | 0.437 | $0.45 | sda-2026-04-01-gap-0 |
| #140 | Selective OGA Inhibition as 'Tau Stabilization' Strategy Without Phosphorylation Cross-Talk | MGEA5 (OGA) | 0.433 | $0.44 | SDA-2026-04-13-gap-d |
| #141 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | AQP1 | 0.431 | $0.44 | sda-2026-04-01-gap-v |
| #142 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.430 | $0.44 | sda-2026-04-01-gap-9 |
| #143 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.430 | $0.44 | sda-2026-04-01-gap-0 |
| #144 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.430 | $0.44 | sda-2026-04-01-gap-0 |
| #145 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.429 | $0.44 | sda-2026-04-01-gap-0 |
| #146 | R-Loop Resolution Enhancement Therapy | SETX | 0.428 | $0.44 | sda-2026-04-01-gap-v |
| #147 | Complement C1QA Spatial Gradient in Cortical Layers | C1QA | 0.428 | $0.44 | analysis-SEAAD-20260 |
| #148 | Extracellular Matrix Stiffness Modulation | PIEZO1 | 0.427 | $0.44 | sda-2026-04-01-gap-0 |
| #149 | APOE-Mediated Synaptic Lipid Raft Stabilization | SPTLC1 | 0.426 | $0.44 | sda-2026-04-01-gap-a |
| #150 | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | RHOT1 | 0.426 | $0.44 | sda-2026-04-01-gap-2 |
| #151 | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | ANXA1 | 0.424 | $0.43 | sda-2026-04-01-gap-v |
| #152 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | AGER | 0.424 | $0.43 | SDA-2026-04-01-gap-2 |
| #153 | Serine/Arginine-Rich Protein Kinase Modulation | SRPK1 | 0.423 | $0.43 | sda-2026-04-01-gap-0 |
| #154 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.423 | $0.43 | SDA-2026-04-03-gap-c |
| #155 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | NURR1, PITX3, neuronal identity transcription factors | 0.423 | $0.43 | SDA-2026-04-03-gap-c |
| #156 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.422 | $0.43 | SDA-2026-04-01-gap-l |
| #157 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.420 | $0.43 | sda-2026-04-01-gap-9 |
| #158 | Synthetic Biology Rewiring via Orthogonal Receptors | CNO | 0.420 | $0.43 | sda-2026-04-01-gap-0 |
| #159 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.418 | $0.43 | sda-2026-04-01-gap-2 |
| #160 | Liquid-Liquid Phase Separation Modifier Therapy | G3BP1 | 0.416 | $0.43 | sda-2026-04-01-gap-9 |
| #161 | Low Complexity Domain Cross-Linking Inhibition | TGM2 | 0.415 | $0.42 | sda-2026-04-01-gap-0 |
| #162 | HDAC2-Specific Repression of PU.1 Pioneer Factor Target Sites Suppresses the IL-33/ST2-Phagocytic Axis; HDAC2 Deletion Specifically Unmasks These Enhancers | HDAC2 | 0.415 | $0.42 | SDA-2026-04-13-gap-p |
| #163 | VCP-Mediated Autophagy Enhancement | VCP | 0.415 | $0.42 | SDA-2026-04-04-gap-t |
| #164 | CX43 hemichannel engineering enables size-selective mitochondrial transfer | GJA1 | 0.415 | $0.42 | sda-2026-04-01-gap-v |
| #165 | Glial Glycocalyx Remodeling Therapy | HSPG2 | 0.415 | $0.42 | sda-2026-04-01-gap-0 |
| #166 | Piezoelectric Nanochannel BBB Disruption | CLDN5, OCLN | 0.414 | $0.42 | sda-2026-04-01-gap-0 |
| #167 | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery | RAB27A | 0.414 | $0.42 | sda-2026-04-01-gap-v |
| #168 | Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics | SLC16A2 | 0.412 | $0.42 | sda-2026-04-01-gap-0 |
| #169 | Biorhythmic Interference via Controlled Sleep Oscillations | GABRA1 | 0.412 | $0.42 | sda-2026-04-01-gap-0 |
| #170 | TREM2 Conformational Stabilizers for Synaptic Discrimination | TREM2 | 0.411 | $0.42 | sda-2026-04-01-gap-v |
| #171 | Temporal TET2-Mediated Hydroxymethylation Cycling | TET2 | 0.408 | $0.42 | SDA-2026-04-04-gap-e |
| #172 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.408 | $0.42 | SDA-2026-04-01-gap-2 |
| #173 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.407 | $0.42 | SDA-2026-04-01-gap-l |
| #174 | Mitochondrial RNA Granule Rescue Pathway | SYNCRIP | 0.400 | $0.41 | sda-2026-04-01-gap-v |
| #175 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.399 | $0.41 | SDA-2026-04-04-gap-e |
| #176 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.399 | $0.41 | sda-2026-04-01-gap-0 |
| #177 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.398 | $0.41 | SDA-2026-04-02-gap-v |
| #178 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.398 | $0.41 | SDA-2026-04-03-gap-a |
| #179 | Brain Insulin Resistance with Glucose Transporter Dysfunction | GLUT3/GLUT4 | 0.398 | $0.41 | SDA-2026-04-02-gap-v |
| #180 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.398 | $0.41 | SDA-2026-04-02-gap-v |
| #181 | Oligodendrocyte White Matter Vulnerability | MOG | 0.398 | $0.41 | SDA-2026-04-03-gap-a |
| #182 | Complement-Mediated Synaptic Pruning Dysregulation | C1QA | 0.398 | $0.41 | SDA-2026-04-03-gap-a |
| #183 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.395 | $0.40 | sda-2026-04-01-gap-v |
| #184 | Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange | PANX1 | 0.386 | $0.40 | sda-2026-04-01-gap-2 |
| #185 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.386 | $0.40 | sda-2026-04-01-gap-v |
| #186 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.385 | $0.39 | sda-2026-04-01-gap-v |
| #187 | Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins | CX3CR1 | 0.384 | $0.39 | sda-2026-04-01-gap-v |
| #188 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.384 | $0.39 | sda-2026-04-01-gap-9 |
| #189 | Mitochondrial SPM Synthesis Platform Engineering | ALOX5 | 0.383 | $0.39 | sda-2026-04-01-gap-0 |
| #190 | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer | GAP43 | 0.380 | $0.39 | sda-2026-04-01-gap-v |
| #191 | KDM6A-Mediated H3K27me3 Rejuvenation | KDM6A | 0.379 | $0.39 | sda-2026-04-01-gap-v |
| #192 | Nucleolar Stress Response Normalization | NPM1 | 0.378 | $0.39 | sda-2026-04-01-gap-v |
| #193 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.378 | $0.39 | sda-2026-04-01-gap-2 |
| #194 | Mitochondrial Calcium Buffering Enhancement via MCU Modulation | MCU | 0.376 | $0.39 | sda-2026-04-01-gap-0 |
| #195 | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | IDH2 | 0.376 | $0.39 | sda-2026-04-01-gap-0 |
| #196 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.374 | $0.38 | sda-2026-04-01-gap-9 |
| #197 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.370 | $0.38 | sda-2026-04-01-gap-2 |
| #198 | Pharmacological Enhancement of APOE4 Glycosylation | ST6GAL1, FUT8 | 0.366 | $0.38 | sda-2026-04-01-gap-0 |
| #199 | DNMT1-Targeting Antisense Oligonucleotide Reset | DNMT1 | 0.359 | $0.37 | sda-2026-04-01-gap-v |
| #200 | Synthetic Biology Approach: Designer Mitochondrial Export Systems | Synthetic fusion proteins | 0.358 | $0.37 | sda-2026-04-01-gap-2 |
| #201 | Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery | TRAK1_KIF5A | 0.348 | $0.36 | sda-2026-04-01-gap-v |
| #202 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.340 | $0.35 | SDA-2026-04-04-gap-t |
| #203 | Synaptic Vesicle Tau Capture Inhibition | SNAP25 | 0.340 | $0.35 | SDA-2026-04-04-gap-t |
| #204 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.340 | $0.35 | SDA-2026-04-04-gap-t |
| #205 | Quantum Coherence Disruption in Cellular Communication | TUBB3 | 0.336 | $0.35 | sda-2026-04-01-gap-0 |
| #206 | Netrin-1 Gradient Restoration | NTN1 | 0.327 | $0.34 | sda-2026-04-01-gap-0 |